Chia‐Cheng Su
Impact in
- Toxicology top 10%
- Bioactive Compounds and Antitumor Agents
-
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Protein Tyrosine Phosphatases 2
- Surgery 8
- Bladder and Urothelial Cancer Treatments 5
- Urinary and Genital Oncology Studies 4
- Co-authors
- Chia‐Yang Li (12 shared papers)Po‐Len Liu (11 shared papers)Wei‐Chung Cheng (11 shared papers)Shu‐Chi Wang (11 shared papers)Shih‐Hua Fang (5 shared papers)Ming‐Yii Huang (2 shared papers)Shu‐Pin Huang (8 shared papers)Hsin‐Chih Yeh (8 shared papers)
In The Last Decade
Chia‐Cheng Su
23 papers receiving 373 citations
Peers
Comparison fields: 5 of 83
- Toxicology 23
- Cancer Research 56
- Pharmacology 31
- Immunology 75
- Neurology 29
Countries citing papers authored by Chia‐Cheng Su
This map shows the geographic impact of Chia‐Cheng Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chia‐Cheng Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chia‐Cheng Su more than expected).
Fields of papers citing papers by Chia‐Cheng Su
This network shows the impact of papers produced by Chia‐Cheng Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chia‐Cheng Su. The network helps show where Chia‐Cheng Su may publish in the future.
Co-authors
The 25 scholars most cited alongside Chia‐Cheng Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 66 | |
| 2 | 2019 | 54 | |
| 3 | 2018 | 37 | |
| 4 | 2021 | 27 | |
| 5 | 2021 | 27 | |
| 6 | 2014 | 23 | |
| 7 | 2016 | 23 | |
| 8 | 2020 | 22 | |
| 9 | 2021 | 17 | |
| 10 | 2022 | 17 | |
| 11 | 2012 | 16 | |
| 12 | 2022 | 7 | |
| 13 | 2019 | 7 | |
| 14 | 2018 | 6 | |
| 15 | 2020 | 5 | |
| 16 | 2023 | 4 | |
| 17 | 2018 | 4 | |
| 18 | 2022 | 3 | |
| 19 | 2022 | 2 | |
| 20 | 2021 | 2 |
About Chia‐Cheng Su
Chia‐Cheng Su is a scholar working on Molecular Biology, Surgery, Urology, Pulmonary and Respiratory Medicine and Rheumatology, having authored 25 papers that have together received 373 indexed citations. Recurring topics across this work include Urological Disorders and Treatments (6 papers), Bladder and Urothelial Cancer Treatments (5 papers), Urinary and Genital Oncology Studies (4 papers), Prostate Cancer Treatment and Research (3 papers), Protein Tyrosine Phosphatases (2 papers), Galectins and Cancer Biology (2 papers), Cancer, Lipids, and Metabolism (2 papers) and Urinary Bladder and Prostate Research (2 papers). The work is most often cited by research in Toxicology (23 citations), Cancer Research (56 citations), Pharmacology (31 citations), Immunology (75 citations) and Neurology (29 citations). Chia‐Cheng Su has collaborated with scholars based in Taiwan and Japan. Frequent co-authors include Chia‐Yang Li, Po‐Len Liu, Wei‐Chung Cheng, Shu‐Chi Wang, Shih‐Hua Fang, Ming‐Yii Huang, Shu‐Pin Huang, Hsin‐Chih Yeh, Chi‐Shuo Chen and Kun‐Hung Shen. Their work appears in journals such as Scientific Reports, The FASEB Journal, International Journal of Molecular Sciences, European Journal of Pharmacology and Integrative Cancer Therapies.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.